Canada wasn’t mentioned by the Company in the Q1 Earnings Call, didn’t appear as an anticipated milestone in their presentation and wasn’t asked about by the analysts. I take that to mean that the Q3 2025 launch target no longer exists.
As it stands, Canada’s Drug Agency has recommended against government reimbursement of DayBue. It says Acadia would have to reduce its price by 98%+. That’s simply not going to happen.
Dependent upon the detail of Trump’s “Most Favored Nation” drug pricing executive order, Acadia may choose to abandon seeking government reimbursement for DayBue in Canada and simply engage with private insurers instead. Roughly half of the Canadian population relies upon private health cover for prescription drug reimbursement.
NEU Price at posting:
$12.02 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)